Published in New England Journal of Medicine · View the paper (DOI)
The Moderna COVID-19 vaccine has demonstrated a 94.1 percent efficacy in preventing symptomatic COVID-19 infections and severe illness, according to the results of the ongoing phase 3 clinical trial. The study enrolled over 30,000 participants and found that cases of severe COVID-19 occurred only in those who received the placebo.
Coverage from 2 institutions